UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 4, 2008
Sucampo Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
| | | | | |
| Delaware | | 001-33609 | | 13-3929237 |
| |
| (State or Other Juris- | | (Commission | | (IRS Employer |
| diction of Incorporation) | | File Number) | | Identification No.) |
| | | |
| 4520 East-West Highway, Suite 300 | | 20814 |
| Bethesda, Maryland | | |
| |
| (Address of Principal Executive Offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (301) 961-3400
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (seeGeneral Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On October 4, 2008, Sucampo Pharmaceuticals, Inc. delivered a scientific conference presentation at the 2nd World Conference on Magic Bullets (Ehrlich II) and American College of Gastroenterology that included written communication comprised of a presentation and poster. The presentation and poster at the 2nd World Conference on Magic Bullets (Ehrlich II) and American College of Gastroenterology are being furnished as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K.
The information in this Item 8.01 and Exhibits 99.1 and 99.2 to this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
| | 99.1 | | Presentation for the 2nd World Conference on Magic Bullets (Ehrlich II), dated October 4, 2008 |
| |
| | 99.2 | | Poster for American College of Gastroenterology, dated October 4, 2008 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | | SUCAMPO PHARMACEUTICALS, INC. |
| | | | | |
| Date: October 7, 2008 | | By: | | /s/ JAN SMILEK |
| | | | | |
| | | | | Name: Jan Smilek |
| | | | | Title: VP, Finance and Acting Chief Financial Officer |
